ProMIS Neurosciences Inc. ((PMN)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ProMIS Neurosciences Inc. is conducting a Phase 1b clinical study titled ‘A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer’s Disease.’ The study aims to evaluate the safety and preliminary efficacy of PMN310, a monoclonal antibody, in patients with early Alzheimer’s disease.
The intervention being tested is PMN310, a humanized immunoglobulin G1 (IgG1) monoclonal antibody, administered via intravenous infusion. The study includes three cohorts with escalating doses of 350 mg, 700 mg, and 1400 mg, compared against a placebo.
This interventional study is randomized and follows a sequential intervention model with double masking for both participants and investigators. The primary purpose is treatment-focused, aiming to assess the drug’s impact on early Alzheimer’s symptoms.
The study began on December 16, 2024, with the latest update submitted on September 3, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The ongoing study could significantly impact ProMIS Neurosciences’ stock performance, as positive results may boost investor confidence and market valuation. In the competitive Alzheimer’s treatment landscape, advancements in PMN310 could position ProMIS as a key player.
The study is currently recruiting, with further details available on the ClinicalTrials portal.